Group 1 - Upbound Group (UPBD) shares have increased by 5% over the past four weeks, closing at $26.29, with a mean price target of $36.63 indicating a potential upside of 39.3% [1] - The mean estimate consists of eight short-term price targets with a standard deviation of $8.07, where the lowest estimate suggests a 1.1% decline and the highest predicts a 90.2% increase to $50 [2] - Analysts show strong agreement in revising UPBD's earnings estimates higher, which correlates with potential stock price increases [4][11] Group 2 - The Zacks Consensus Estimate for UPBD's current year earnings has risen by 0.3% over the past month, with no negative revisions [12] - UPBD holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While price targets may not be entirely reliable, the direction they imply suggests a positive outlook for UPBD [13]

Core Viewpoint - Vertical Aerospace Ltd. (EVTL) has shown a significant price increase of 32% over the past four weeks, with a mean price target of $10.30 indicating a potential upside of 93.6% from its current price of $5.32 [1] Price Targets and Analyst Consensus - The average price targets for EVTL range from a low of $2 to a high of $15, with a standard deviation of $5.14, indicating variability in analyst estimates [2] - The lowest estimate suggests a decline of 62.4%, while the highest points to an upside of 182% [2] - A low standard deviation among price targets suggests a strong agreement among analysts regarding the stock's price direction [9] Earnings Estimates and Analyst Optimism - Analysts have shown growing optimism regarding EVTL's earnings prospects, as indicated by a strong consensus in revising EPS estimates higher [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 100%, with two estimates moving higher and no negative revisions [12] - EVTL holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13]

Core Viewpoint - European Wax Center, Inc. (EWCZ) has shown a significant price increase of 51.5% over the past four weeks, with a mean price target of $6.50 indicating a potential upside of 27.7% from the current trading price of $5.09 [1] Price Targets and Analyst Consensus - The average price targets for EWCZ range from a low of $4 to a high of $15, with a standard deviation of $3.51, indicating variability in analyst estimates [2] - The lowest estimate suggests a decline of 21.4%, while the most optimistic estimate indicates a potential upside of 194.7% [2] - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Optimism - Analysts have shown strong agreement in revising EWCZ's earnings estimates higher, which correlates with potential stock price increases [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 127.1%, with four estimates moving higher and no negative revisions [12] - EWCZ holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - Solely relying on price targets for investment decisions may not be wise, as analysts' ability to set unbiased targets has been questioned [3][10] - Analysts often set overly optimistic price targets due to business incentives, which can lead to inflated estimates [8]

Group 1 - Xperi (XPER) has shown a 7.3% increase in stock price over the past four weeks, with a mean price target of $18.25 indicating a potential upside of 134.3% [1] - The mean estimate includes four short-term price targets with a standard deviation of $8.02, suggesting variability in analyst predictions; the lowest estimate of $12 indicates a 54% increase, while the highest estimate suggests a 285.1% increase to $30 [2] - Analysts show strong agreement on XPER's ability to report better earnings than previously predicted, which supports the view of potential upside [4] Group 2 - The Zacks Consensus Estimate for XPER has increased by 46.2% over the past month, with no negative revisions, indicating positive earnings momentum [12] - XPER holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates, which is a strong indicator of potential upside [13] - While consensus price targets may not be reliable for predicting exact stock gains, they can provide a directional guide for price movement [13]

Core Viewpoint - Spyre Therapeutics (SYRE) shows significant upside potential with a mean price target of $53.50, indicating a 244.1% increase from its current price of $15.55 [1] Price Targets and Estimates - The mean estimate consists of 10 short-term price targets with a standard deviation of $16.36, suggesting variability among analysts [2] - The lowest estimate of $21 indicates a 35.1% increase, while the highest estimate predicts a surge of 356.6% to $71 [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement [9] Analyst Sentiment and Earnings Estimates - Analysts exhibit growing optimism about SYRE's earnings prospects, as evidenced by a positive trend in earnings estimate revisions [11] - The Zacks Consensus Estimate for the current year has increased by 5.7% over the past month, with two estimates rising and no negative revisions [12] - SYRE holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13]

Market players were eager to push the start button on Nintendo (NTDOY 5.13%) stock as the trading week drew to a close. Shares of the storied Japanese video game company finished Friday up by more than 5% thanks in no small part to an analyst's price-target increase. That rise was in contrast to the S&P 500's dip of 0.4%.A bull gets more bullishBefore market open that day, JPMorgan Chase's Junko Yamamura lifted her fair value assessment on Nintendo's Japan-listed stock to 15,300 yen ($106.52) per share, up ...

Group 1 - Impinj (PI) shares have increased by 52.5% in the past four weeks, closing at $117.52, with a mean price target of $149.50 indicating a potential upside of 27.2% [1] - The mean estimate consists of eight short-term price targets with a standard deviation of $55.04, where the lowest estimate is $100 (14.9% decline) and the highest is $251 (113.6% increase) [2] - Analysts show strong agreement in revising earnings estimates higher, with the Zacks Consensus Estimate for the current year increasing by 102.6% over the past month [11][12] Group 2 - The Zacks Rank for PI is 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] - While price targets are often viewed as important, they can mislead investors, and analysts may set overly optimistic targets due to business incentives [7][8] - A low standard deviation in price targets indicates a high degree of agreement among analysts regarding the stock's price movement, serving as a starting point for further research [9]

Shares of Altimmune, Inc. (ALT) have gained 39.4% over the past four weeks to close the last trading session at $5.80, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $22.38 indicates a potential upside of 285.9%.The mean estimate comprises eight short-term price targets with a standard deviation of $5.32. While the lowest estimate of $12 indicates a 106.9% increase from the cur ...

Astrazeneca (AZN) closed the last trading session at $67.30, gaining 3.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $86.07 indicates a 27.9% upside potential.The mean estimate comprises 10 short-term price targets with a standard deviation of $10.38. While the lowest estimate of $67 indicates a 0.5% decline from the current price level, the most optimistic analyst expects the ...

Shares of Upbound Group (UPBD) have gained 10.1% over the past four weeks to close the last trading session at $24.17, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $37.88 indicates a potential upside of 56.7%.The average comprises eight short-term price targets ranging from a low of $30 to a high of $50, with a standard deviation of $7.12. While the lowest estimate indicates ...